Bridged Nucleic Acids (BNA)
The use of antibody-drug conjugates (ADCs) as guided missiles to target a specific
group of cells with fewer side affects than traditional cancer treatment. The goal
is to create a new molecule by conjugate drug with anti-cancer toxin attributes
to antibodies and create a new molecule that essentially is greater than the sum
of its parts by making it more targeted with stronger cytotoxic affect. Bio-Synthesis's
bioconjugation-based drug discovery and development programs has built on over 30
years of experience in providing high quality conjugate complexes, commitment to
R&D, and stringetn IP protection, our contract drug development program offer
a comprehensive bioconjugation strategies that can be custom designed and developed
to fit your needs. From design and development of conjugation strategy; feasibility
studies; process development to purification and bioanalytical assessments, we have
developed and delivered numerous drug bioconjugates such as:
While traditional antibody conjugation takes advantage of lysine ϵ-amino , N-terminal
α-amine groups or carboxylate groups due to its abundance in antibody, the conjugation
procedure that tilize these groups often changes tthe overall pI of the antibody
and leads to higher nonspecific binding. In addition, this random cross-linking
within antibody often obscuring the binding sites and may produce partially active
or inactive antiobdy conjugates tha tmay not bind to the antigen.
Bio-Synthesis offers site-specific antibody -drug conjugation services based on
the unique conjugation strategy developed at Bio-Synthesis. Small drugs or
toxins can be conjugated to an antibody at a specific site away from the antigen
binding site. Site-specific cross-linking resutls in:
Peptide-drug conjugates (PDCs) developed at Bio-Synthesis using unique conjugation
strategy. These drug molecule can be modified or conjugated at specific site on
the peptide at customer's request.
Oligo-drug conjugates can be synthesized, modified, conjugate and characterized
in our laboratories using site specific conjugation chemistries. Various oligonucleotide
analogs can be preapre in our laboratory and conjugate with bioactive molecules,
lipids, polymers to improve cellular uptake, pharmacokinetic properties and specificity
towrd the tartet tissues/cells.
At Bio-Synthesis, custom bioconjugation complexes are manufactured under a strict
quality control process to assure customers' complete satisfaction. Our sizeable
investment in state-of-the-art analytical equipment provides industry-leading tools
to develop and monitor our process. Complementary techniques, such as analytical
chromatography and electrophoresis, MALDI-TOF, ESI, LC-MS are routinely used to
verify that specifications are met. At Bio-Synthesis, we strive with competence
and confidence to meet your demand for developing pre-clinical drug candidates or
innovative regents and tools efficiently and affordably. With our track record,
Bio-Synthesis is your ideal and reliable innovation partner in targeted drug discovery.
Contact our Technical Service Center at 800.220.0627 or contact us online
with your detail project specifications, a project manager will be assigned to help
you with design and develop an appropreate synthetic method for your specific needs.
Bio-Synthesis can assist our customer to conjugate peptide, oligonucleotides, antibody,
carbohydrate with antibiotic, vitamine, anticancer drugs and other synthetic and
natural drug compounds.
Vitamine A, B1, B12, C and D conjugation, biotin can be cross-linked antibody, peptide/protein,
oligonucleotides and other type of macromolecules.
We can provide conjugate antibody, peptide/protein or oligo/nucleic acid with antibiotic
such as: Amoxicillin, clenbuterol, ractopamine, chloramphenicol, Salbutamol, Sulfamethazine,
Sulfonamide group, Sulfadiazine, Sulfafurazole, Sulformetoxine, Sulfamethoxypyridazine,Sulfaguanidine,
Sulfathiodiazole,Sulfamethoxazole, Sulfamethoxypyridazine, Sulfaguanidine, Sulfathiodiazole,
Sulphamethoxydiazine, Sulfamonomethoxine, Madribon, Sulfaquinoxaline, Du-6859a,
Streptomycin, Gentamycin,Ampicillin, Tetracycline
List of available cancer drug can be used to conjugate with antibody, peptide/protein,
oligonucleotide for targeted therapeutic are:
Doxorubicin, Epirubicin, Daunorubicin, Idarubicin, Elsamicin A, Actinomycin D, Bleomycin,
Mithramycin, Taxol (Paclitaxel), Docetaxel, Tesetaxel, Vincristine, Vinblastine,
Navelbine, Etoposie (VP-16), Beacizumab (Avastin), Cisplatin, Carboplatin, Erlotinib,
Mitoxantrone, Busulfan, Nitrogen mustards, Uramustine, Chloroambucil, Melphalan,
Cyclophophamid, Ifosfamide, Carmustine, Lomustine, Semustine, Procarbazine, Mitomycin,
Praziquantel, Irinotecan, Topotecan, Methotrexate, Pemetrexed, lapatinib, Ambroxol,
Demecolcine, CCP (3-cyano-2-chloropyridine), Tegafur-uracil, Mercaptopurine Thioguanine,
Ara-C (cytarabine), Gemcitabine, Lamivudine, Capecitabine, Nelarabine, Fludarabine,
Leustatin, Dacarbazine, Hydroxyurea, Rituximab, Tumor necrosis factor.
Aspirin, Ibuprofen, Ketoprofen, 5-Azacytidine, methotrexate, Lisinopril, Pravastatin,
Memantine Hydrocloride, Propranolol
Price varies based on the proejct specifications. Price
does not includes cost of small molecule or biopolymer which requireed to be supplied
by customer or order through Bio-Synthesis from a commercial vendor. Some of the
small molecules are commerically available in an activated form. For non-active
molecules, Bio-Synthesis can assit with the design and, if deemed necessary,
biopolymer modification to introduce additional functional groups and extra
linkers. Please contact us for a quote.
Using preactivated small molecule and biomolecule with
chemical reactive groups such as amine, thiol, carboxylate, hydroxyl, aldehyde and
ketone, active hydrogen, photo-chemial and cycloadition reactions and cross link
via zero-length , homobifunctional, heterobiofunctional or multifunctioanl cross-linking
chemistries, denrimer and dendrons, cleavable regent system.
After standard desalting, or purification,
a small percent of heterogeneous products containing single or multi-site conjugate
per molecule may exist.
All custom synthesis of biomolecule, modification or
bioconjugation services are manufactured under strict quality control processes.
Analytical HPLC and MS analyses are performed in every development cycle. Final
target conjugates must first be isolated from excess or unreacted reagent. In many
cases, simple dialysis may suffice to remove unreacted reagent from the reaction
solution. Depending on the project scope, size-exclusion chromatography (SEC), HPLC,
may also be used to either remove excess reagent or isolate and characterized the
cross-linked product. Cross-linked target molecule may then be further characterized
by biochemical or biophysical techniques. Once the product has been purified, it
may be subject to many different types of studies including spectroscopic (MALDI-top,
ESI, LC-MS Fluorescence), electrophoresis, immunochemical biochemical, enzymatical
analysis. QC (quality control) and QA (quality assurance) procedures are also followed
independently to offer you double guarantee for the highest quality possible of
every delivered conjugates. Moreover, our dedicated technical account managers will
guide your project through every step of the process and constantly keep you informed
of the latest project progress.
The typical delivery consisted of lyophilized
sample in individual fully labeled vials, shipment also contain COA, MS, HPLC and/or
other analytical data . Additional analytical data also available upon requests.
For us to better understand your customized project, please complete our Bioconjugation Service Questionnaire. The more our chemists understand your project needs, the more accurate feedback we will be able to provide you. Provide us with your project details will enable to us to recommend the best reagents to use for your project. The most useful and readily available tools for bioconjugation projects are cross-linking reagents. A large number of cross-linkers, also known as bifunctional reagents, have been developed. There are several ways to classify the cross-linkers, such as the type of reactive group, hydrophobicity or hydrophilicity, and the length of the spacer between reactive groups. Other factors to consider are whether the two reactive groups are the same or different (for example, heterobifunctional or homobifunctional reagents), whether the spacer is cleavable, and whether the reagents are membrane permeable or impermeable. The most accessible and abundant reactive groups in proteins are the ϵ-amino groups of lysine. Therefore, a large number of the most common cross-linkers are amino selective reagents, such as imidoesters, sulfo-N-hydroxysuccinimide esters, and N-hydroxysuccinimide esters. Due to the high reactivity of the thiol group with N-ethylmaleimide, iodoacetate and a-halocarbonyl compounds, new cross-linkers have been developed that contain maleimide and a-carbonyl moieties. Usually, N-alkylmaleimides aremore stable than their N-aryl counterparts.
In addition to the reactive groups on the cross-linkers, a wide variety of connectors and spacer arms have also been developed. The nature and length of the spacer arm play an important role in the functionality. Longer spacer arms are generally more effective when coupling large proteins or those with sterically protected reactive side-chains. Other important considerations are the hydrophobicity, hydrophilicity, and the conformational flexibility. Long aliphatic chains generally fold on themselves when in an aqueous environment, which makes the actual distance spanned by such linker arms less than expected. Instead, spacers that contain more rigid structures (for example, aromatic groups or cycloalkanes) should be used. These structures, however, tend to be very hydrophobic which could significantly decrease the solubility of the modified molecules or even modify some of their properties. In such cases, it is recommended to choose a spacer that contains an alkylether (PEO) chain. Bio-Synthesis offers several cross-linkers with PEO chains, such as thiol-binding homobifunctional reagents, heterobifunctional based, and their derivatives.
Within 3-5 days upon receiving your project scope, we will provide you an appropriate quotation. An order can be placed with PO (Purchase Order) or major credit cards ( ). Your credit card will be billed under Bio-Synthesis, Inc.